- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FDA Approves Capivasertib Plus Fulvestrant in Advanced HR+/HER2– Breast Cancer With PIK3CA, AKT1, or PTEN Alterations
The FDA has approved capivasertib plus fulvestrant for the treatment of patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer harboring 1 or more PIK3CA, AKT1, or PTEN alteration, following progression on at least 1 endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.
This article was originally published by OncLive®.
The FDA has approved capivasertib (Truqap) in combination with fulvestrant (Faslodex) for the treatment of adult patients with hormone receptor–positive, HER2-negative, locally advanced or metastatic breast cancer harboring 1 or more PIK3CA, AKT1, or PTEN alteration, as detected by an FDA-approved test, following progression on at least 1 endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.1
The regulatory decision was based on data from the phase 3 CAPItello-291 trial (NCT04305496), where findings demonstrated that among 289 patients with PIK3CA/AKT1/PTEN-altered tumors, the combination of capivasertib and fulvestrant (n = 155) elicited a median progression-free survival (PFS) of 7.3 months (95% CI, 5.5-9.0) vs 3.1 months (95% CI, 2.0-3.7) for placebo plus fulvestrant (n = 134; HR 0.50; 95% CI, 0.38, 0.65; P < .0001).
FDA Approved | Image credit: Olivier Le Moal - stock.adobe.com
In the overall population, patients treated in the capivasertib arm (n = 355) experienced a median PFS of 7.2 months (95% CI, 5.5-7.4) vs 3.6 months (95% CI, 2.8-3.7) for those given placebo plus fulvestrant (n = 353; HR, 0.60; 95% CI, 0.51-0.71; P < .001).2
Notably, an exploratory analysis of 313 patients without PIK3CA/AKT1/PTEN alterations showed that treatment with the combination led to a numerical but not statistically significant improvement in PFS (HR, 0.79; 95% CI, 0.61, 1.02), indicating that the PFS difference in the overall population could primarily be attributed to the benefits seen in patients with PIK3CA/AKT1/PTEN-altered tumors.1
The randomized, double-blind, placebo-controlled, multicenter trial enrolled in 708 patients with locally advanced or metastatic hormone receptor–positive, HER2-negative breast cancer, including 289 patients whose tumors harbored PIK3CA/AKT1/PTEN alterations. Adult patients needed to have histologically confirmed disease following recurrence or progression during or after aromatase inhibitor therapy, with or without a CDK4/6 inhibitor, and up to 1 line of chemotherapy for advanced disease.2
HER2 negativity was defined as immunohistochemistry (IHC) 0 or 1+, or IHC 2+/negative in situ hybridization.
Patients were randomly assigned in a 1:1 fashion to receive 400 mg of oral capivasertib 400 mg or placebo twice per day for 4 days, followed by 3 days off, in 28-day treatment cycles. In both arms, patients also received 500 mg of intramuscular fulvestrant on days 1 and 15 of cycle 1, then once every 28 days thereafter. Treatment continued until disease progression or unacceptable toxicity.
The co-primary end points of the trial were PFS in the overall patient population and in the population of patients whose tumors had PIK3CA, AKT1 or PTEN alterations in the AKT pathway. Secondary end points included overall survival (OS), objective response rate, and safety. Patient-reported end points included the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (QLQ-C30).
The most common adverse effects (AEs) that occurred in at leasts 20% of patients treated in the capivasertib arm included diarrhea, cutaneous adverse reactions, increased random glucose, decreased lymphocytes, decreased hemoglobin, increased fasting glucose, nausea, fatigue, decreased leukocytes, increased triglycerides, decreased neutrophils, increased creatinine, vomiting, and stomatitis.1
AEs led to dose interruption in 34.9% of patients receiving capivasertib vs 10.3% of patients receiving placebo. Dose reductions occurred in 19.7% of patients given capivasertib vs 1.7% given placebo. AEs leading to treatment discontinuation were reported in 13.0% and 2.3% of patients, respectively.2
References
1. FDA approves capivasertib with fulvestrant for breast cancer. News release. FDA. November 16, 2023. Accessed November 16, 2023. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capivasertib-fulvestrant-breast-cancer
2. Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in hormone receptor–positive advanced breast cancer. N Engl J Med. 2023;388(22):2058-2070. doi:10.1056/NEJMoa2214131
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
The Disproportionate Impact of the Pandemic on Health Care Disparities and Cancer
February 22nd 2022On this episode of Managed Care Cast, we discuss how already wide health care inequities in cancer are becoming much worse because of the COVID-19 pandemic, with guest Monica Soni, MD, associate chief medical officer at New Century Health.
Listen
